Dendritic cells: An important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases

Clinical Immunology

Volumn 146, Issue 3, 2013, Pages 197-206

  Broder, Anna ^a   Chan, Jimmy J ^a   Putterman, Chaim ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Atherosclerosis; Dendritic cells

Indexed keywords

PHOSPHOLIPID ANTIBODY; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; TOLL LIKE RECEPTOR; UBIQUITIN;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNITY; CELL STIMULATION; DENDRITIC CELL; ENDOTHELIAL DYSFUNCTION; GLYCATION; HUMAN; INNATE IMMUNITY; NONHUMAN; PERIODONTAL DISEASE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; THROMBOSIS;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ATHEROSCLEROSIS; AUTOIMMUNE DISEASES; DENDRITIC CELLS; ENDOTHELIUM, VASCULAR; HUMANS;

EID: 84873879763     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2012.12.002     Document Type: Review

References (68)

1. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J. Autoimmun. 2000, 15:145-151.
2. Levine J.S., Branch D.W., Rauch J. The antiphospholipid syndrome. N. Engl. J. Med. 2002, 346:752-763.
3. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., Derksen R.H., PG D.E.G., Koike T., Meroni P.L., Reber G., Shoenfeld Y., Tincani A., Vlachoyiannopoulos P.G., Krilis S.A. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 2006, 4:295-306.
4. Meroni P.L., Borghi M.O., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat. Rev. Rheumatol. 2011, 7:330-339.
5. Pierangeli S.S., Chen P.P., Raschi E., Scurati S., Grossi C., Borghi M.O., Palomo I., Harris E.N., Meroni P.L. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin. Thromb. Hemost. 2008, 34:236-250.
6. Matsuura E., Shen L., Matsunami Y., Quan N., Makarova M., Geske F.J., Boisen M., Yasuda S., Kobayashi K., Lopez L.R. Pathophysiology of beta2-glycoprotein I in antiphospholipid syndrome. Lupus 2010, 19:379-384.
7. de Groot P.G., Urbanus R.T. The significance of autoantibodies against beta2-glycoprotein I. Blood 2012, 120:266-274.
8. Ames P.R., Margarita A., Alves J.D. Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome. Clin. Rev. Allergy Immunol. 2009, 37:29-35.
9. Jara L.J., Medina G., Vera-Lastra O. Systemic antiphospholipid syndrome and atherosclerosis. Clin. Rev. Allergy Immunol. 2007, 32:172-177.
10. Jara L.J., Medina G., Vera-Lastra O., Shoenfeld Y. Atherosclerosis and antiphospholipid syndrome. Clin. Rev. Allergy Immunol. 2003, 25:79-88.
11. Matsuura E., Lopez L.R., Shoenfeld Y., Ames P.R. Beta2-glycoprotein I and oxidative inflammation in early atherogenesis: a progression from innate to adaptive immunity?. Autoimmun. Rev. 2012, 12(2):241-249.
12. McMahon M., Hahn B.H. Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr. Opin. Immunol. 2007, 19:633-639.
13. Narshi C.B., Giles I.P., Rahman A. The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus?. Lupus 2011, 20:5-13.
14. Profumo E., Buttari B., Alessandri C., Conti F., Capoano R., Valesini G., Salvati B., Rigano R. Beta2-glycoprotein I is a target of T cell reactivity in patients with advanced carotid atherosclerotic plaques. Int. J. Immunopathol. Pharmacol. 2010, 23:73-80.
15. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 2011, 17:1410-1422.
16. Hansson G.K. Regulation of immune mechanisms in atherosclerosis. Ann. N. Y. Acad. Sci. 2001, 947:157-165. (discussion 165-6).
17. Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1876-1890.
18. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352:1685-1695.
19. Virella G., Atchley D., Koskinen S., Zheng D., Lopes-Virella M.F. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin. Immunol. 2002, 105:81-92.
20. Keaney J.F. Immune modulation of atherosclerosis. Circulation 2011, 124:e559-e560.
21. Broder A., Tobin J.N., Putterman C. High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: cross-sectional study. J. Clin. Pathol. 2012, 65:551-556.
22. Artenjak A., Lakota K., Frank M., Cucnik S., Rozman B., Bozic B., Shoenfeld Y., Sodin-Semrl S. Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review. Autoimmun. Rev. 2012, 11(12):873-882.
23. Rutella S., De Cristofaro R., Ferraccioli G. Function and dysfunction of dendritic cells in autoimmune rheumatic diseases. Hum. Immunol. 2009, 70:360-373.
24. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
25. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18:767-811.
26. Murphy K., Travers P., Walport M., Janeway C. Janeway's Immunobiology 2008, Garland Science, New York.
27. Steinman R.M., Idoyaga J. Features of the dendritic cell lineage. Immunol. Rev. 2010, 234:5-17.
28. Ketelhuth D.F., Hansson G.K. Cellular immunity, low-density lipoprotein and atherosclerosis: break of tolerance in the artery wall. Thromb. Haemost. 2011, 106:779-786.
29. Levine J.S., Subang R., Koh J.S., Rauch J. Induction of anti-phospholipid autoantibodies by beta2-glycoprotein I bound to apoptotic thymocytes. J. Autoimmun. 1998, 11:413-424.
30. Price B.E., Rauch J., Shia M.A., Walsh M.T., Lieberthal W., Gilligan H.M., O'Laughlin T., Koh J.S., Levine J.S. Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2-glycoprotein I-dependent manner. J. Immunol. 1996, 157:2201-2208.
31. Tolomeo T., Rico De Souza A., Roter E., Dieude M., Amireault P., Subang R., Levine J.S., Rauch J. T cells demonstrate a Th1-biased response to native beta2-glycoprotein I in a murine model of anti-phospholipid antibody induction. Autoimmunity 2009, 42:292-295.
32. Rovere P., Manfredi A.A., Vallinoto C., Zimmermann V.S., Fascio U., Balestrieri G., Ricciardi-Castagnoli P., Rugarli C., Tincani A., Sabbadini M.G. Dendritic cells preferentially internalize apoptotic cells opsonized by anti-beta2-glycoprotein I antibodies. J. Autoimmun. 1998, 11:403-411.
33. Gaipl U.S., Beyer T.D., Baumann I., Voll R.E., Stach C.M., Heyder P., Kalden J.R., Manfredi A., Herrmann M. Exposure of anionic phospholipids serves as anti-inflammatory and immunosuppressive signal-implications for antiphospholipid syndrome and systemic lupus erythematosus. Immunobiology 2003, 207:73-81.
34. Kuwana M., Matsuura E., Kobayashi K., Okazaki Y., Kaburaki J., Ikeda Y., Kawakami Y. Binding of beta 2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood 2005, 105:1552-1557.
35. Bondanza A., Rovere-Querini P., Zimmermann V.S., Balestrieri G., Tincani A., Sabbadini M.G., Manfredi A.A. Requirement for dendritic cells in the establishment of anti-phospholipid antibodies. Autoimmunity 2007, 40:302-306.
36. Hurst J., Prinz N., Lorenz M., Bauer S., Chapman J., Lackner K.J., von Landenberg P. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells. Immunobiology 2009, 214:683-691.
37. Prinz N., Clemens N., Strand D., Putz I., Lorenz M., Daiber A., Stein P., Degreif A., Radsak M., Schild H., Bauer S., von Landenberg P., Lackner K.J. Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells. Blood 2011, 118:2322-2332.
38. Kleinbongard P., Heusch G., Schulz R. TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol. Ther. 2010, 127:295-314.
39. Dunoyer-Geindre S., de Moerloose P., Galve-de Rochemonteix B., Reber G., Kruithof E.K. NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies. Thromb. Haemost. 2002, 88:851-857.
40. Denny M.F., Thacker S., Mehta H., Somers E.C., Dodick T., Barrat F.J., McCune W.J., Kaplan M.J. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007, 110:2907-2915.
41. Buttari B., Profumo E., Capozzi A., Sorice M., Rigano R. Oxidized human beta2-glycoprotein I: its impact on innate immune cells. Curr. Mol. Med. 2011, 11:719-725.
42. Buttari B., Profumo E., Mattei V., Siracusano A., Ortona E., Margutti P., Salvati B., Sorice M., Rigano R. Oxidized beta2-glycoprotein I induces human dendritic cell maturation and promotes a T helper type 1 response. Blood 2005, 106:3880-3887.
43. George J., Harats D., Gilburd B., Afek A., Levy Y., Schneiderman J., Barshack I., Kopolovic J., Shoenfeld Y. Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 1999, 99:2227-2230.
44. Pamukcu B., Lip G.Y., Shantsila E. The nuclear factor-kappa B pathway in atherosclerosis: a potential therapeutic target for atherothrombotic vascular disease. Thromb. Res. 2011, 128:117-123.
45. Kinev A.V., Roubey R.A. Tissue factor in the antiphospholipid syndrome. Lupus 2008, 17:952-958.
46. Buttari B., Profumo E., Capozzi A., Facchiano F., Saso L., Sorice M., Rigano R. Advanced glycation end products of human beta(2) glycoprotein I modulate the maturation and function of DCs. Blood 2011, 117:6152-6161.
47. Mohar D.S., Barseghian A., Haider N., Domanski M., Narula J. Atherosclerosis in chronic kidney disease: lessons learned from glycation in diabetes. Med. Clin. North Am. 2012, 96:57-65.
48. Cerami A., Vlassara H., Brownlee M. Protein glycosylation and the pathogenesis of atherosclerosis. Metabolism 1985, 34:37-42.
49. Muslin A.J. MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin. Sci. (Lond.) 2008, 115:203-218.
50. Liu Z., Cao W. p38 mitogen-activated protein kinase: a critical node linking insulin resistance and cardiovascular diseases in type 2 diabetes mellitus. Endocr. Metab. Immune Disord. Drug Targets 2009, 9:38-46.
51. Amital H., Govoni M., Maya R., Meroni P.L., Ori B., Shoenfeld Y., Tincani A., Trotta F., Sarzi-Puttini P., Atzeni F. Role of infectious agents in systemic rheumatic diseases. Clin. Exp. Rheumatol. 2008, 26:S27-S32.
52. Lockhart P.B., Bolger A.F., Papapanou P.N., Osinbowale O., Trevisan M., Levison M.E., Taubert K.A., Newburger J.W., Gornik H.L., Gewitz M.H., Wilson W.R., Smith S.C., Baddour L.M. Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association?: a scientific statement from the American Heart Association. Circulation 2012, 125:2520-2544.
53. Seymour G.J., Ford P.J., Cullinan M.P., Leishman S., Yamazaki K. Relationship between periodontal infections and systemic disease. Clin. Microbiol. Infect. 2007, 13(Suppl. 4):3-10.
54. Schenkein H.A., Gunsolley J.C., Best A.M., Harrison M.T., Hahn C.L., Wu J., Tew J.G. Antiphosphorylcholine antibody levels are elevated in humans with periodontal diseases. Infect. Immun. 1999, 67:4814-4818.
55. Schenkein H.A., Best A.M., Brooks C.N., Burmeister J.A., Arrowood J.A., Kontos M.C., Tew J.G. Anti-cardiolipin and increased serum adhesion molecule levels in patients with aggressive periodontitis. J. Periodontol. 2007, 78:459-466.
56. Barbour S.E., Ishihara Y., Fakher M., Al-Darmaki S., Caven T.H., Shelburne C.P., Best A.M., Schenkein H.A., Tew J.G. Monocyte differentiation in localized juvenile periodontitis is skewed toward the dendritic cell phenotype. Infect. Immun. 2002, 70:2780-2786.
57. Blank M., Krause I., Fridkin M., Keller N., Kopolovic J., Goldberg I., Tobar A., Shoenfeld Y. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J. Clin. Invest. 2002, 109:797-804.
58. Vaarala O., Alfthan G., Jauhiainen M., Leirisalo-Repo M., Aho K., Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993, 341:923-925.
59. Tew J.G., El Shikh M.E., El Sayed R.M., Schenkein H.A. Dendritic cells, antibodies reactive with oxLDL, and inflammation. J. Dent. Res. 2012, 91:8-16.
60. Martin F., Dixit V.M. A20 edits ubiquitin and autoimmune paradigms. Nat. Genet. 2011, 43:822-823.
61. Kool M., van Loo G., Waelput W., De Prijck S., Muskens F., Sze M., van Praet J., Branco-Madeira F., Janssens S., Reizis B., Elewaut D., Beyaert R., Hammad H., Lambrecht B.N. The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity 2011, 35:82-96.
62. Musone S.L., Taylor K.E., Nititham J., Chu C., Poon A., Liao W., Lam E.T., Ma A., Kwok P.Y., Criswell L.A. Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases. Genes Immun. 2011, 12:176-182.
63. Shang F., Gong X., Taylor A. Activity of ubiquitin-dependent pathway in response to oxidative stress. Ubiquitin-activating enzyme is transiently up-regulated. J. Biol. Chem. 1997, 272:23086-23093.
64. Grune T., Reinheckel T., Davies K.J. Degradation of oxidized proteins in mammalian cells. FASEB J. 1997, 11:526-534.
65. Versari D., Herrmann J., Gossl M., Mannheim D., Sattler K., Meyer F.B., Lerman L.O., Lerman A. Dysregulation of the ubiquitin-proteasome system in human carotid atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2132-2139.
66. Hermansson A., Johansson D.K., Ketelhuth D.F., Andersson J., Zhou X., Hansson G.K. Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice. Circulation 2011, 123:1083-1091.
67. Hjerpe C., Johansson D., Hermansson A., Hansson G.K., Zhou X. Dendritic cells pulsed with malondialdehyde modified low density lipoprotein aggravate atherosclerosis in Apoe(-/-) mice. Atherosclerosis 2010, 209:436-441.
68. Torres-Aguilar H., Blank M., Kivity S., Misgav M., Luboshitz J., Pierangeli S.S., Shoenfeld Y. Tolerogenic dendritic cells inhibit antiphospholipid syndrome derived effector/memory CD4(+) T cell response to beta2GPI. Ann. Rheum. Dis. 2012, 71:120-128.